Recently, the Bairesi Pills jointly developed by Wuhan Renfu Innovative Drug Research and Development Center Co.
, Ltd.
, a wholly-owned subsidiary of Renfu Pharmaceutical Group, and the Uyghur Medical Research Institute of Xinjiang Uygur Autonomous Region received the approval notice for drug clinical trials issued by the State Food and Drug Administration
.
Bairesi Pill is derived from the nosocomial preparations included in the "Preparation Standards for Uyghur Medical and Medical Institutions in Xinjiang Uygur Autonomous Region".
It is applied for clinical trials in accordance with the requirements of Class 1.
1 innovative traditional Chinese medicines in the registration classification of traditional Chinese medicines, and is intended to be used for the treatment of stable vitiligo
.
At present, calcineurin inhibitors, vitamin D3 derivatives and hormone drugs are mainly used in the clinical treatment of vitiligo
.
As a cooperative research and development project, the ownership and disposal rights of Bairesi Pills related technologies and their intellectual property rights belong to Wuhan Renfu Innovative Drug Research and Development Center
.
According to the requirements of laws and regulations related to drug registration in China, Wuhan Renfu Innovative Drug Research and Development Center and Xinjiang Uygur Autonomous Region Uyghur Medical Research Institute will start the work related to clinical research of drugs after receiving the notice of drug clinical trial
.
